JP2026010001A5 - - Google Patents
Info
- Publication number
- JP2026010001A5 JP2026010001A5 JP2025168147A JP2025168147A JP2026010001A5 JP 2026010001 A5 JP2026010001 A5 JP 2026010001A5 JP 2025168147 A JP2025168147 A JP 2025168147A JP 2025168147 A JP2025168147 A JP 2025168147A JP 2026010001 A5 JP2026010001 A5 JP 2026010001A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- edaravone
- dispersant
- humans
- suspension according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018207646 | 2018-11-02 | ||
| JP2018207646 | 2018-11-02 | ||
| JP2020554977A JP7274502B2 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
| PCT/JP2019/043013 WO2020091036A1 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
| JP2023075654A JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075654A Division JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026010001A JP2026010001A (ja) | 2026-01-21 |
| JP2026010001A5 true JP2026010001A5 (enExample) | 2026-05-18 |
Family
ID=70463399
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554977A Active JP7274502B2 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
| JP2023075654A Active JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
| JP2025168147A Pending JP2026010001A (ja) | 2018-11-02 | 2025-10-06 | 経口投与用エダラボン懸濁剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554977A Active JP7274502B2 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
| JP2023075654A Active JP7828317B2 (ja) | 2018-11-02 | 2023-05-01 | 経口投与用エダラボン懸濁剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10987341B2 (enExample) |
| EP (2) | EP3875085B1 (enExample) |
| JP (3) | JP7274502B2 (enExample) |
| KR (1) | KR20210087490A (enExample) |
| CN (4) | CN117398346A (enExample) |
| AR (1) | AR116967A1 (enExample) |
| AU (2) | AU2019369843A1 (enExample) |
| BR (1) | BR112021008197A2 (enExample) |
| DK (1) | DK3875085T3 (enExample) |
| ES (1) | ES2991523T3 (enExample) |
| FI (1) | FI3875085T3 (enExample) |
| HU (1) | HUE068117T2 (enExample) |
| IL (2) | IL319280A (enExample) |
| MX (3) | MX2021005144A (enExample) |
| PH (1) | PH12021550988A1 (enExample) |
| PL (1) | PL3875085T3 (enExample) |
| PT (1) | PT3875085T (enExample) |
| SG (1) | SG11202104365QA (enExample) |
| WO (1) | WO2020091036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019167178A1 (ja) | 2018-02-28 | 2019-09-06 | 田辺三菱製薬株式会社 | ３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬を含む薬剤の製造方法 |
| MX2021005144A (es) | 2018-11-02 | 2021-07-15 | Mitsubishi Tanabe Pharma Corp | Suspension de edaravona para administracion oral. |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| CA3198014A1 (en) | 2020-11-12 | 2022-05-19 | Hidetoshi Shimizu | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| GB202103807D0 (en) | 2021-03-18 | 2021-05-05 | Johnson Matthey Plc | A crystalline salt of edaravone, processes for the preparation and use thereof |
| JPWO2023149539A1 (enExample) | 2022-02-03 | 2023-08-10 | ||
| WO2024005187A1 (ja) | 2022-07-01 | 2024-01-04 | 田辺三菱製薬株式会社 | 組成物、およびエダラボンの応答可能性の評価方法 |
| US12343330B2 (en) | 2023-02-16 | 2025-07-01 | Slayback Pharma Llc | Stable pharmaceutical compositions of edaravone |
| CN118178328A (zh) * | 2024-03-21 | 2024-06-14 | 药云(西安)医药技术有限公司 | 依达拉奉包埋物制备方法与其口服制剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH07121861B2 (ja) | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| JPH1120463A (ja) | 1997-06-30 | 1999-01-26 | Zexel Corp | 車両用デュアルエアコン |
| WO2002034264A1 (en) | 2000-10-24 | 2002-05-02 | Mitsubishi Pharma Corporation | Remedies for amyotrophic lateral sclerosis (als) |
| JP2004091441A (ja) | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
| US20080161378A1 (en) | 2004-02-09 | 2008-07-03 | Hiide Yoshino | Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) or Diseases Caused by Als |
| JP5836004B2 (ja) | 2010-08-12 | 2015-12-24 | 日新化成株式会社 | 可溶化剤 |
| CN102824356A (zh) | 2012-09-25 | 2012-12-19 | 江西中医学院 | 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法 |
| WO2014134243A1 (en) | 2013-02-27 | 2014-09-04 | Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
| JP6336246B2 (ja) | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | ナノ粒子化製剤及びその製造方法 |
| CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
| EP3247334A1 (en) | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
| JP7026609B2 (ja) * | 2016-03-10 | 2022-02-28 | 大日本住友製薬株式会社 | 微細粒子含有組成物およびその製法 |
| CN113768879A (zh) * | 2016-03-16 | 2021-12-10 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| PL3551181T3 (pl) | 2017-01-17 | 2021-05-31 | Treeway Tw001 B.V. | Leczenie obejmujące doustne lub dożołądkowe podawanie edarawonu |
| AU2017394478B2 (en) * | 2017-01-17 | 2023-07-20 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
| CA3069048A1 (en) * | 2017-07-06 | 2019-01-10 | Treeway Tw001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
| MX2021005144A (es) * | 2018-11-02 | 2021-07-15 | Mitsubishi Tanabe Pharma Corp | Suspension de edaravona para administracion oral. |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION |
-
2019
- 2019-11-01 MX MX2021005144A patent/MX2021005144A/es unknown
- 2019-11-01 BR BR112021008197-6A patent/BR112021008197A2/pt unknown
- 2019-11-01 PT PT198807703T patent/PT3875085T/pt unknown
- 2019-11-01 CN CN202311552337.9A patent/CN117398346A/zh active Pending
- 2019-11-01 DK DK19880770.3T patent/DK3875085T3/da active
- 2019-11-01 AR ARP190103206A patent/AR116967A1/es unknown
- 2019-11-01 EP EP19880770.3A patent/EP3875085B1/en active Active
- 2019-11-01 CN CN201980072370.7A patent/CN112969459B/zh active Active
- 2019-11-01 WO PCT/JP2019/043013 patent/WO2020091036A1/ja not_active Ceased
- 2019-11-01 EP EP24181935.8A patent/EP4420724A3/en active Pending
- 2019-11-01 ES ES19880770T patent/ES2991523T3/es active Active
- 2019-11-01 PL PL19880770.3T patent/PL3875085T3/pl unknown
- 2019-11-01 JP JP2020554977A patent/JP7274502B2/ja active Active
- 2019-11-01 CN CN202311552338.3A patent/CN117379369A/zh active Pending
- 2019-11-01 IL IL319280A patent/IL319280A/en unknown
- 2019-11-01 FI FIEP19880770.3T patent/FI3875085T3/fi active
- 2019-11-01 AU AU2019369843A patent/AU2019369843A1/en not_active Abandoned
- 2019-11-01 IL IL282773A patent/IL282773B2/en unknown
- 2019-11-01 HU HUE19880770A patent/HUE068117T2/hu unknown
- 2019-11-01 SG SG11202104365QA patent/SG11202104365QA/en unknown
- 2019-11-01 KR KR1020217016462A patent/KR20210087490A/ko active Pending
- 2019-11-01 CN CN202311552339.8A patent/CN117379370A/zh active Pending
-
2020
- 2020-05-12 US US16/872,741 patent/US10987341B2/en active Active
-
2021
- 2021-03-26 US US17/213,501 patent/US11241416B2/en active Active
- 2021-04-30 MX MX2023009973A patent/MX2023009973A/es unknown
- 2021-04-30 PH PH12021550988A patent/PH12021550988A1/en unknown
- 2021-04-30 MX MX2024000663A patent/MX2024000663A/es unknown
- 2021-12-23 US US17/560,493 patent/US11478450B2/en active Active
-
2022
- 2022-09-22 US US17/934,234 patent/US11957660B2/en active Active
-
2023
- 2023-05-01 JP JP2023075654A patent/JP7828317B2/ja active Active
-
2024
- 2024-03-26 US US18/616,227 patent/US12599586B2/en active Active
-
2025
- 2025-07-21 AU AU2025205635A patent/AU2025205635A1/en active Pending
- 2025-10-06 JP JP2025168147A patent/JP2026010001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020091036A5 (enExample) | ||
| CN101137350B (zh) | 包含利福昔明的胃稳定药物制剂 | |
| CN1127340C (zh) | 含烟碱复合物的组合物、该组合物的应用及其形成方法 | |
| US6537582B2 (en) | Anti-inflammatory pharmaceutical formulations | |
| JP4098620B2 (ja) | 抗結核剤の新規な医薬組成物及びその調製方法 | |
| JP4209467B2 (ja) | 経口投与用製剤組成物 | |
| JPH07316052A (ja) | 直腸内投与組成物 | |
| KR20090123860A (ko) | 실로스타졸을 함유하는 제어방출 제제 및 이의 제조방법 | |
| CA2704946A1 (en) | Compositions for the treatment of inflammation of the gastrointestinal tract | |
| JP2004503484A (ja) | 多孔質セレコキシブマトリックスおよびその製造方法 | |
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2019108366A5 (enExample) | ||
| CN1479611A (zh) | 包含酸不稳定活性成分的糊剂形式的药物制剂 | |
| JP2021169504A (ja) | アプレピタント経口液体製剤 | |
| US8753682B2 (en) | Dual release oral tablet compositions of dexlansoprazole | |
| CN1398184A (zh) | 具有改善的生物利用度和缩小的个体内和个体间吸收差异的含有伊曲康唑的组合物 | |
| JP2018516266A5 (enExample) | ||
| JP2774135B2 (ja) | 固体の急速に崩壊する剤形 | |
| JP2024544572A (ja) | Ｒｏｃｋ２阻害剤のナノ結晶製剤およびその調製方法 | |
| CN100528232C (zh) | 包含酸不稳定活性成分的混悬液形式的药物制剂 | |
| JP2020510660A5 (enExample) | ||
| US8563035B2 (en) | Oral tablet compositions of dexlansoprazole | |
| TWI780270B (zh) | 固體分散體 | |
| CN1642537A (zh) | 用于硬壳胶囊的布洛芬溶液 | |
| JP2015528515A (ja) | 胃食道疾患を治療するための方法および組成物 |